Allopurinol
Term · Oncology and biomedicine · MLC-T-ONC-000400
A drug that lowers high levels of uric acid (a byproduct of metabolism) in the blood caused by some cancer treatments.
A structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies.
| Identifier | MLC-T-ONC-000400 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | 4'-HPP |
| Synonyms | zurinol |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-000400",
"term": "Allopurinol",
"field": "Oncology and biomedicine",
"definitions": [
"A drug that lowers high levels of uric acid (a byproduct of metabolism) in the blood caused by some cancer treatments.",
"A structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies."
],
"abbreviation": "4'-HPP",
"synonyms": [
"zurinol"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/allopurinol/"
}
Record 848 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.